RYTM
Rhythm
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Strong Buy"
EPS Beats Expectation
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About RYTM
Rhythm Pharmaceuticals, Inc.
A commercial-stage biopharmaceutical company focused on the treatment of hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases
222 Berkeley Street, 12th Floor, Boston, MA 02116
--
Rhythm Pharmaceuticals, Inc., a Delaware corporation, was founded in February 2013. The company is a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients and their families with rare neuroendocrine diseases. The company is focused on advancing melanocortin -4 receptor agonists, including their main asset, IMCIVREE, as a precision drug designed to treat hyperappetite and severe obesity caused by rare MC4R pathway diseases.
Company Financials
EPS
RYTM has released its 2024 Q4 earnings. EPS was reported at -0.72, versus the expected -0.73, beating expectations. The chart below visualizes how RYTM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RYTM has released its 2024 Q4 earnings report, with revenue of 41.83M, reflecting a YoY change of 72.61%, and net profit of -43.29M, showing a YoY change of -3.98%. The Sankey diagram below clearly presents RYTM’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
